Last updated: June 7, 2026
ecutive summary: Suppliers for diatrizoate meglumine and diatrizoate sodium span branded and generic manufacturers, with sourcing typically split between (1) API/active ingredient makers and (2) finished-dose producers for X-ray contrast media. The practical supplier landscape is dominated by large-scale sterile manufacturing networks and established contrast-media API supply chains.
What companies supply diatrizoate meglumine and diatrizoate sodium (X-ray contrast) in the US and EU?
Diatrizoate meglumine and diatrizoate sodium are iodinated contrast agents used for radiographic imaging. Market supply is concentrated among generic and branded contrast-media producers with sterile-manufacturing capabilities and established distribution for radiology settings.
Primary finished-dose suppliers (contrast products)
Suppliers are usually identified by the finished contrast product manufacturer listed on US labeling and by the firms marketing the product under NDCs in the US, and by marketing authorization holders in the EU. For business procurement, these firms are the practical contracting counterparties because they control sterile filling, labeling, and distribution.
API suppliers versus finished-dose manufacturers
Procurement often distinguishes:
- API/starting material suppliers for iodinated intermediates and finished diatrizoate salts
- Finished-dose manufacturers that produce sterile aqueous injection formulations
In tenders and hospital pharmacy contracts, buyers typically purchase finished contrast products, with API sourcing visibility limited unless an intermediary supplies the API under a defined supply agreement.
Supplier selection criteria buyers use in practice
- Sterile manufacturing capacity (aseptic processing, container closure validation)
- Supply reliability (allocated production, multi-source capability)
- Regulatory track record (FDA registration, EU QMS alignment)
- Iodine concentration parity (exact strength matching to avoid workflow substitutions)
- Package configuration (vials vs bottles, batch size consistency)
Who makes the active ingredient (API) for diatrizoate meglumine and diatrizoate sodium?
API production for iodinated contrast agents is specialized. The API supply chain can involve:
- Synthesis of the diatrizoate core and iodination steps
- Salt formation to produce meglumine and sodium salts
- Solids handling and conversion into injection-grade intermediates
- Downstream formulation, sterile filtration, and final aseptic filling by finished-dose makers
API supply model in the contrast-media market
Many contrast products are produced by manufacturers who either:
- Purchase API from specialized iodinated-chemistry suppliers, or
- Integrate API synthesis and finished-dose manufacturing in-house
From a buyer perspective, the API supplier role is less visible than the finished-dose supplier role because finished-dose contracts drive actual availability to imaging centers.
How many suppliers are active for diatrizoate meglumine and diatrizoate sodium globally?
The global supplier count is limited by:
- Need for sterile manufacturing and radiology-grade QA release
- Regulatory approvals and product-specific manufacturing controls
- Chemistry and iodinated intermediate handling constraints
As a result, many countries show a small number of qualifying finished-dose manufacturers at any time, even if API-level suppliers are more numerous.
What products and dosing forms do suppliers provide for diatrizoate contrast?
Suppliers typically offer diatrizoate salts in sterile aqueous injection presentations used for imaging.
Common commercial presentations
- Single-dose vials or multi-dose bottle formats
- Concentrations aligned to prescribing standards and radiology protocols
- Packaging configured for department workflow and stock rotation
Substitution and compatibility issues
Procurement should align:
- Strength (iodine content concentration)
- Salt form (meglumine vs sodium)
- Volume per container
- Labeling language and indications
Which suppliers are most relevant for US hospital procurement of diatrizoate meglumine and diatrizoate sodium?
Hospital procurement prioritizes contracted suppliers with consistent distribution and documented batch performance. The relevant suppliers are the companies that hold:
- US NDC listings for diatrizoate-containing injectable contrast products
- Distribution networks into group purchasing organizations and hospital formularies
How does supplier availability affect generic entry and backorder risk for diatrizoate?
Contrast-media supply is sensitive to:
- Sterile filling line utilization
- Batch-cycle disruptions and quality holds
- Raw material availability for iodinated intermediates
- Packaging material lead times
Supplier concentration means that when a leading manufacturer’s batch run is disrupted, shortages can propagate across the distribution network.
What licensing and manufacturing arrangements govern diatrizoate contrast supply?
Supplier relationships often use:
- Manufacturing and distribution agreements between API and finished-dose firms
- Tech transfer arrangements for sterile filling lines
- Private-label or co-marketing agreements for NDC bundling
- Regulatory responsibility allocation between marketing authorization holder and manufacturer
These arrangements are typically reflected in product labeling and regulatory documentation, which buyers and their consultants use to map who actually manufactures the sterile product.
What is the regulatory status of diatrizoate contrast products that determines supplier qualification?
In the US, the key regulatory gate for suppliers is FDA market access for the specific finished drug product. In Europe, suppliers must hold or work under a marketing authorization for each product presentation.
FDA listing mechanics that influence suppliers
- FDA drug listing ties a product to an NDC and labeler identity
- Finished-dose manufacturing ties to GMP-inspected facilities
EU authorization mechanics
- Marketing authorization holder and manufacturing site separation is common
- Batch release and QMS controls drive supplier eligibility for tender awards
How do diatrizoate meglumine and diatrizoate sodium suppliers compare with iohexol and iopamidol suppliers?
Procurement comparison is typically done on:
- Clinical protocol fit
- Product strength and injection characteristics
- Supply continuity history
- Price per container and contract volume discounts
While iohexol and iopamidol have broader supplier ecosystems in many regions, diatrizoate supply can be narrower due to the combination of sterile production needs and older product supply dynamics.
Key supplier mapping workflow for procurement teams
To lock down reliable supply for diatrizoate meglumine and diatrizoate sodium, procurement typically builds a supplier map by:
- Identifying NDC-linked labelers for each finished-dose presentation used clinically
- Verifying manufacturer sites through labeling and regulatory references
- Cross-checking availability against historical order fill rates
- Setting multi-source contracts with at least one alternate finished-dose supplier per presentation
Key Takeaways
- Supplier availability for diatrizoate meglumine and diatrizoate sodium is dominated by finished-dose contrast-media manufacturers with sterile manufacturing capacity and established distribution into radiology channels.
- API supply exists in a specialized iodinated-chemistry segment, but procurement outcomes are driven by finished-dose supplier contracts tied to NDCs and packaging presentations.
- Supplier concentration increases backorder risk when sterile filling capacity or batch release is constrained.
- The highest value supplier due diligence is mapping NDC labelers to actual manufacturing sites, then building multi-source procurement per container strength and format.
FAQs
- How do I identify the actual manufacturer of a diatrizoate meglumine or diatrizoate sodium product behind a specific NDC?
- What packaging configurations of diatrizoate contrast products are most interchangeable across hospitals?
- Which supply risks most often cause shortages for iodinated contrast agents like diatrizoate?
- Can diatrizoate meglumine and diatrizoate sodium products be substituted one-for-one in radiology workflows?
- How do procurement teams structure multi-source contracts for contrast media when supplier concentration is high?
References (APA)
- FDA. (n.d.). Drug products and databases (NDC-related drug listing resources). US Food and Drug Administration. https://www.fda.gov
- EMA. (n.d.). European medicines regulatory information and marketing authorization resources. European Medicines Agency. https://www.ema.europa.eu
